FDA approves label update to Novo Nordisk’s Tresiba diabetes drug

The FDA approved Novo Nordisk‘s (NYSE:NVO) request to include heart health data on the label of its Tresiba insulin degludec product.

The Danish insulin-maker evaluated its Type II diabetes drug in a 7,637-patient trial, assessing the therapy for cardiovascular safety compared to insulin glargine.

Get the full story at our sister site, Drug Delivery Business News.

 

The post FDA approves label update to Novo Nordisk’s Tresiba diabetes drug appeared first on MassDevice.

from MassDevice https://ift.tt/2G8PnZM